Marshall Wace
TLIS

Marshall Wace’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Marshall Wace’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-755
Closed -$125K – 3524
2021
Q2 		$125K Sell
755
-3,066
-80% -$521K ﹤0.01% 2520
2021
Q1 		$737K Buy
+3,821
New +$953K ﹤0.01% 1793

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's TLIS Position: Q3 2021 in Review

Marshall Wace sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2021, closing a stake of 755 shares — an estimated $125K sold.

Marshall Wace first reported a position in TLIS in Q1 2021 and held it in 2 quarters. The position peaked at $737K in Q1 2021. 38 funds tracked by Wall St. Rank hold TLIS as of Q3 2021.

  • Marshall Wace reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace sold 755 Talis Biomedical Corporation Common Stock shares in Q3 2021, an estimated $125K.
  • Marshall Wace first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 2 quarters.
  • Marshall Wace's Talis Biomedical Corporation Common Stock position peaked at $737K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2021.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.